Cerebrolysin
Cognitive, Repair and Recovery
Cerebrolysin is a mixture of many low-molecular-weight peptides and amino acids rather than a single molecule, so no one half-life describes it. The 3.5 h figure previously shown here was not supportable.
In short
- A porcine brain-derived peptide mixture, not a defined single compound — which changes how every claim about it should be read.
- Registered as a medicine in Russia, China, and a number of other countries; NOT approved in the US, EU, or UK.
- Has genuinely large randomised trials behind it, including CASTA in acute stroke — which did not meet its primary endpoint.
- Cochrane reviews have been unfavourable, citing risk of bias and no convincing evidence of benefit in acute stroke.
- Being animal-derived, it carries biological-product considerations that synthetic peptides do not.
Structure
Cerebrolysin is a MIXTURE of low-molecular-weight peptides and free amino acids derived from purified porcine brain protein, not a single molecule. There is no structure to draw and no single half-life to state — which is why this entry corrects the numeric half-life the library previously showed.
How it works
Cerebrolysin is produced by enzymatic breakdown of purified porcine brain proteins, yielding a mixture of low-molecular-weight peptides and free amino acids. The manufacturer describes neurotrophic activity mimicking endogenous factors such as BDNF, GDNF, and CNTF.
Proposed mechanisms include neuroprotection against excitotoxicity, reduced apoptosis, modulation of amyloid processing, and support of neuroplasticity.
The fundamental interpretive problem is that a mixture cannot have a clean mechanism, a clean dose-response, or a clean pharmacokinetic profile. Batch composition can vary, and which components carry activity is not established.
What the research shows
Acute ischaemic stroke: the CASTA trial, a large randomised placebo-controlled study, did not meet its primary endpoint. Some post-hoc subgroup analyses in more severe strokes reported signal.
Vascular dementia and Alzheimer disease: multiple trials report cognitive improvement, mostly from centres in countries where the product is registered.
Traumatic brain injury: some positive reports, methodologically variable.
Cochrane assessments have been consistently unfavourable, citing risk of bias and insufficient evidence of benefit. The gap between the volume of published positive results and the assessments of independent reviewers is the defining feature of this evidence base.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — acute ischaemic stroke trials (CASTA and similar) | 30 mL daily by infusion for 10 days | intravenous infusion | PubMed |
| Human — dementia trials | 10–30 mL daily in courses of 4 weeks, repeated | intravenous infusion | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 1–5 mL daily in courses of 10–20 days | intramuscular |
Trial protocols used INTRAVENOUS INFUSION in hospital settings at volumes far above community intramuscular use. Note also that this is dosed by volume of a mixture, not by mass of an active compound, so "dose" here means something different than it does elsewhere in this library.
Handling and storage
Supplied as a ready-made solution in ampoules, not as a lyophilised powder — it does not require reconstitution.
Clinical protocols use intravenous infusion in courses. Intramuscular injection at lower volumes is the community route.
As an animal-derived biological product, sourcing and storage integrity matter more than for synthetic peptides, and there is no way to verify either from a research-market vial.
Side effects
In the clinical trials, generally reported as well tolerated. Injection-site reactions, dizziness, headache, and occasional agitation are described.
Because it is porcine-derived, hypersensitivity and allergic reactions are a genuine consideration in a way they are not for synthetic peptides.
Rapid infusion is associated with more adverse effects, which is why clinical protocols infuse slowly.
Animal-derived biologicals also carry theoretical transmissible-agent considerations, managed by manufacturing controls that cannot be verified in grey-market supply.
Combinations
In clinical use it is administered as monotherapy in defined courses rather than combined.
No interaction data exists. Combining a mixture of unknown active components with other neuroactive compounds makes attribution impossible in both directions.
Research status
A large published literature, concentrated in Russia, China, Eastern Europe, and Spain, including several sizeable randomised trials.
The critical issue is the divergence between that literature and independent systematic review. Cochrane has repeatedly found the evidence insufficient and at risk of bias. When a body of positive trials fails independent appraisal, the appraisal is usually the more reliable signal.
Legal status
Registered as a prescription medicine in Russia, China, and roughly 40 other countries. NOT approved in the US, EU, UK, Canada, or Australia. Importation for personal use is unlawful in several of those jurisdictions.
WADA status
Not specifically named on the Prohibited List. Falls under WADA class S0, which prohibits any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. Treat it as prohibited in sport.
Conclusion
Cerebrolysin is the most-studied compound in this library that independent reviewers do not believe works.
It is also a porcine-derived mixture rather than a defined molecule, which is why this entry now reports no half-life at all — the 3.5 hour figure previously shown here described nothing real.
Sources
Track your own Cerebrolysin protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.